4889 — Renascience Balance Sheet
0.000.00%
- ¥24bn
- ¥22bn
- ¥133m
Annual balance sheet for Renascience, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1,026 | 2,387 | 2,212 | 2,027 | 1,800 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | 4.46 | 17.7 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,043 | 2,428 | 2,267 | 2,086 | 1,871 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.58 | 3.63 | 4.3 | 0 | — |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,067 | 2,438 | 2,275 | 2,089 | 1,871 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29.4 | 37.9 | 100 | 126 | 151 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 505 | 237 | 410 | 482 | 151 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 562 | 2,201 | 1,865 | 1,607 | 1,720 |
| Total Liabilities & Shareholders' Equity | 1,067 | 2,438 | 2,275 | 2,089 | 1,871 |
| Total Common Shares Outstanding |